![]() |
Name |
Mollicellin Q
|
Molecular Formula | C23H26O7 | |
IUPAC Name* |
11-(ethoxymethyl)-3,10-dihydroxy-2,2,5,8-tetramethyl-3,4-dihydrochromeno[7,6-b][1,4]benzodioxepin-7-one
|
|
SMILES |
CCOCC1=C(C=C(C2=C1OC3=C(C(=C4CC(C(OC4=C3)(C)C)O)C)OC2=O)C)O
|
|
InChI |
InChI=1S/C23H26O7/c1-6-27-10-14-15(24)7-11(2)19-21(14)28-17-9-16-13(8-18(25)23(4,5)30-16)12(3)20(17)29-22(19)26/h7,9,18,24-25H,6,8,10H2,1-5H3
|
|
InChIKey |
RCLMCNQLMYPAFZ-UHFFFAOYSA-N
|
|
Synonyms |
Mollicellin Q
|
|
CAS | NA | |
PubChem CID | 146684102 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 414.4 | ALogp: | 3.3 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 94.4 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.56 |
Caco-2 Permeability: | -5.144 | MDCK Permeability: | 0.00001980 |
Pgp-inhibitor: | 0.102 | Pgp-substrate: | 0.823 |
Human Intestinal Absorption (HIA): | 0.123 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.053 | Plasma Protein Binding (PPB): | 99.47% |
Volume Distribution (VD): | 0.426 | Fu: | 1.41% |
CYP1A2-inhibitor: | 0.269 | CYP1A2-substrate: | 0.752 |
CYP2C19-inhibitor: | 0.141 | CYP2C19-substrate: | 0.272 |
CYP2C9-inhibitor: | 0.272 | CYP2C9-substrate: | 0.333 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.251 |
CYP3A4-inhibitor: | 0.137 | CYP3A4-substrate: | 0.292 |
Clearance (CL): | 8.679 | Half-life (T1/2): | 0.257 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.025 |
Drug-inuced Liver Injury (DILI): | 0.169 | AMES Toxicity: | 0.077 |
Rat Oral Acute Toxicity: | 0.919 | Maximum Recommended Daily Dose: | 0.846 |
Skin Sensitization: | 0.182 | Carcinogencity: | 0.684 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.109 |
Respiratory Toxicity: | 0.811 |